Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 3211 COVERAGE, CODING & PAYMENT AdvaMed continued to work with CMS on coverage issues related to FDA-approved investigational device exemption (IDE) clinical trials and successfully advocated for improvements. In 2016, CMS modified its policy to allow coverage for Medicare beneficiaries that participate in certain IDE trials where historically coverage had been denied for devices deemed experimental or investigational. AdvaMed successfully engaged with the American Medical Association to establish a streamlined submission and updating process for laboratory codes in response to legislation revamping payments for laboratory testing services. These improvements will also allow codes for non-sole-source, FDA-approved in vitro diagnostic tests to go through a more streamlined process for descriptor development and approval. As part of AdvaMed’s Innovation Agenda, the Association continued work developing legislative language to ease burdens associated with coverage of Category III codes and to ensure that breakthrough technologies receiving New Technology Add-on Payments and their associated services are covered and paid. PAYMENT POLICY CONFERENCE AdvaMed hosted its 2nd Annual Payment Policy Conference in April, highlighting innovation challenges for medical technologies. The conference included discussions on the impact of new payment models and their implications for device innovation, adoption and utilization. Speakers addressed a number of emerging areas including value, quality measurement under the new Medicare Incentive Payment System (MIPS), expanded bundling, and telehealth. Wyatt Decker, Mayo Clinic in Arizona CEO (at left) discusses payment and health care delivery challenges with the AdvaMed Board in March, including Chairman Vincent Forlenza of BD (center), and AdvaMed’s Andy Fish (at right).